IL-17A stimulates the progression of giant cell tumors of bone

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4697-4705

  Xu, Meng ^a   Song, Zhi Gang ^a   Xu, Cheng Xiong ^d   Rong, Guang Hua ^b   Fan, Ke Xing ^c   Chen, Ji Ying ^a   Zhang, Wei ^a   Jia, Jin Peng ^a   Han, Gang ^a   Wang, Wei ^a   Chai, Wei ^a   Liang, Wen Tao ^a   Bi, Wen Zhi ^a   Wang, Yan ^a  

^a General Hospital of the Chinese People's Liberation Army   (China)

^b BEIJING 302 HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MESSENGER RNA; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GIANT CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLASTOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADULT; AGED; BONE NEOPLASMS; CARCINOGENESIS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GIANT CELL TUMOR OF BONE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84883475612     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0251     Document Type: Article

References (41)

1. Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, et al. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol 2012;19:916-24.
2. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am 2006;37:35-51. (Pubitemid 41719085)
3. Werner M. Giant cell tumour of bone: morphological, biological, and histogenetical aspects. Int Orthop 2006;30:484-9. (Pubitemid 44900556)
4. Miossec P, Korn T, Kuchroo VK. Mechanisms of disease: interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
5. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest 2011;41:1361-6.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42. (Pubitemid 40852708)
7. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Iinvest 1999;103:1345-52. (Pubitemid 29218305)
8. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82. (Pubitemid 44833343)
9. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AMC, Colin EM, Hazes JMW, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011;63:73-83.
10. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-a antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 2009;108:947-55.
11. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69:106-14. (Pubitemid 17030377)
12. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Pelat Res 1980;2003:4-18.
13. Cowan RW, Mak IW, Colterjohn N, Singh G, Ghert M. Collagenase expression and activity in the stromal cells from giant cell tumour of bone. Bone 2009;44:865-71.
14. Ghert M, Simunovic N, Cowan RW, Colterjohn N, Singh G. Properties of the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res 2007;459:8-13. (Pubitemid 46878187)
15. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009;60:1647-56.
16. Xu CX, Jere D, Jin H, Chang SH, Chung YS, Shin JY, et al. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 2008;178:60-73. (Pubitemid 351919194)
17. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
18. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010;70:10112-20.
19. Wang LH, Jiang YD, Zhang YX, Wang YW, Huang SH, Wang ZH, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS ONE 2012;7:e34400.
20. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol 2006;29:96-9. (Pubitemid 44356723)
21. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song WH, et al. Elevated IL-17 produced by T(H)17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010;115:5385-92.
22. Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 2009;16:1332-43.
23. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology 2008;47:1635-40.
24. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011;32:232-9.
25. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-24.
26. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone 2013;52:238-46.
27. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-52. (Pubitemid 29177183)
28. Singh S, Mak IWY, Cowan RW, Turcotte R, Singh G, Ghert M. The role of TWIST as a regulator in giant cell tumor of bone. J Cell Biochem 2011;112:2287-95.
29. Kim Y, Nizami S, Goto H, Lee FY. Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 2012;4:107-16.
30. Zhang F, Tanaka H, Kawato T, Kitami S, Nakai K, Motohashi M, et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 2011;93:296-305.
31. Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001;127:467-74. (Pubitemid 32662503)
32. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol 2009;21:338-44.
33. Wulling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003;34:983-93. (Pubitemid 37315249)
34. Balla P, Moskovszky L, Sapi Z, Forsyth R, Knowles H, Athanasou NA, et al. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology 2011;59:376-89.
35. Sasaguri Y, Komiya S, Sugama K, Suzuki K, Inoue A, Morimatsu M, et al. Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol 1992;141:611-21.
36. Zheng MH, Fan Y, Wysocki SJ, Lau AT, Robertson T, Beilharz M, et al. Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteo-clast- like cell migration. Am J Pathol 1994;145:1095-104. (Pubitemid 24345657)
37. Thomas DM. RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 2012;24:397-403.
38. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
39. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91. (Pubitemid 41002860)
40. Niida S, Kondo T, Hiratsuka S, Hayashi SI, Amizuka N, Noda T, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A 2005;102:14016-21. (Pubitemid 41377695)
41. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7. (Pubitemid 36857622)